Exciting news in cancer research! Our Biosynth colleagues in Berlin, Frank Leenders and Ralf Krähmer, together with a great team of scientists, published the results of their recent collaboration. The results show promising results in inhibiting tumor growth. PEGylation of Aplysia puntata ink toxin (APIT-PEG) increases its circulation time and stability in vivo.

Read the full article from https://pubs.acs.org/doi/10.1021/acsbiomaterials.4c00473

The PEGylated recombinant production of APIT, an amino acid oxidase that depletes arginine and lysine, leads to a significant dose-dependent reduction in tumor growth over time, mediated by amino acid starvation of the tumor. The enzyme oxidizes the essential amino acids arginine and lysine to their corresponding deaminated alpha-keto acids, depriving auxotrophic cancer cells of these nutrients required for growth. PEGylation preserved APIT's enzyme characteristics while enhancing its in vivo stability after intravenous injection.

Read more about Biosynth publications at https://lnkd.in/ezKBrbn9.

hashtag#pegylation hashtag#Biosynth hashtag#bioconjugation hashtag#cancerresearch

PEGylated Recombinant Aplysia punctata Ink Toxin Depletes Arginine and Lysine and Inhibits the Growth of Tumor Xenografts